| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,383,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.53 - $28.72 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 2 |
| Insider 6 Months : 2 |
| Insider 3/6 Months : 4.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53 |
53 |
53 |
53 |
| Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
101,351 |
146,351 |
179,848 |
214,693 |
| Total Sell Value |
$2,152,463 |
$3,094,133 |
$3,971,419 |
$5,040,525 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
11 |
12 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stafford John S Iii |
10% Owner |
– – • |
2019-12-09 |
4 |
S |
$41.64 |
$5,009,750 |
I/I |
(120,324) |
1,879,676 |
|
- |
|
| Desjarlais John R |
Sr. V.P., Research & CSO |
• – – |
2019-09-06 |
4 |
OE |
$4.25 |
$116,969 |
D/D |
27,522 |
83,868 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2019-08-21 |
4 |
S |
$41.27 |
$1,650,724 |
D/D |
(40,000) |
73,629 |
|
- |
|
| Kuch John J |
Sr. Vice President & CFO |
• – – |
2019-08-21 |
4 |
OE |
$11.05 |
$221,000 |
D/D |
20,000 |
113,629 |
|
- |
|
| Desjarlais John R |
Sr. V.P., Research & CSO |
• – – |
2019-08-19 |
4 |
S |
$40.69 |
$1,424,150 |
D/D |
(35,000) |
56,346 |
|
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-06-06 |
4 |
B |
$29.87 |
$377,587 |
I/I |
12,641 |
5,090,000 |
1.5 |
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-05-02 |
4 |
B |
$29.87 |
$436,407 |
I/I |
14,611 |
5,077,359 |
1.5 |
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-03-25 |
4 |
B |
$29.77 |
$104,195 |
I/I |
3,500 |
5,062,748 |
1.5 |
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-03-22 |
4 |
B |
$29.96 |
$59,920 |
I/I |
2,000 |
5,059,248 |
1.5 |
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-03-18 |
4 |
B |
$29.90 |
$32,890 |
I/I |
1,100 |
5,057,248 |
1.5 |
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2019-03-15 |
4 |
B |
$29.02 |
$1,111,466 |
I/I |
38,300 |
5,056,148 |
1.5 |
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-09-17 |
4 |
AS |
$46.03 |
$1,841,208 |
D/D |
(40,000) |
4,952 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-09-17 |
4 |
OE |
$11.05 |
$442,000 |
D/D |
40,000 |
44,952 |
|
- |
|
| Ronin Capital, Llc |
10% Owner |
– – • |
2018-09-14 |
4 |
S |
$48.05 |
$48,054 |
I/I |
(1,000) |
5,017,848 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-17 |
4 |
S |
$40.10 |
$146,726 |
D/D |
(3,659) |
4,952 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-17 |
4 |
OE |
$11.05 |
$40,432 |
D/D |
3,659 |
8,611 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-16 |
4 |
S |
$41.10 |
$852,373 |
D/D |
(20,739) |
4,952 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-16 |
4 |
OE |
$11.05 |
$229,166 |
D/D |
20,739 |
25,691 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-15 |
4 |
S |
$41.10 |
$4,357 |
D/D |
(106) |
4,952 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-15 |
4 |
OE |
$11.05 |
$1,171 |
D/D |
106 |
5,058 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-14 |
4 |
S |
$41.11 |
$636,980 |
D/D |
(15,496) |
4,952 |
|
- |
|
| Foster Paul A |
Chief Medical Officer |
• – – |
2018-08-14 |
4 |
OE |
$11.05 |
$171,231 |
D/D |
15,496 |
20,448 |
|
- |
|
| Baracchini Edgardo Jr |
Chief Business Officer |
• – – |
2018-08-13 |
4 |
S |
$40.35 |
$513,874 |
D/D |
(12,734) |
207 |
|
- |
|
| Baracchini Edgardo Jr |
Chief Business Officer |
• – – |
2018-08-13 |
4 |
OE |
$11.05 |
$140,711 |
D/D |
12,734 |
12,941 |
|
- |
|
| Baracchini Edgardo Jr |
Chief Business Officer |
• – – |
2018-08-10 |
4 |
S |
$40.03 |
$1,160,045 |
D/D |
(28,983) |
207 |
|
- |
|
312 Records found
|
|
Page 5 of 13 |
|
|
0.75 (3.9%) 
